Trihexyphenidyl
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Trihexyphenidyl
- Trihexyphenidyl: From Unspecified Original Indication to Attention-Deficit/Hyperactivity Disorder
Trihexyphenidyl: From Unspecified Original Indication to Attention-Deficit/Hyperactivity Disorder
One-Sentence Summary
Trihexyphenidyl is a well-established anticholinergic agent; however, its original indication and mechanism of action are not recorded in the available data for this evaluation. The TxGNN model predicts potential efficacy for Attention-Deficit/Hyperactivity Disorder (ADHD), but this direction is currently supported by only 1 tangentially related publication and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified — no data available in the current regulatory record |
| Predicted New Indication | Attention-Deficit/Hyperactivity Disorder (ADHD) |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for trihexyphenidyl in this evaluation. Based on general pharmacological classification, trihexyphenidyl is an anticholinergic agent that acts primarily on the extrapyramidal system, modulating the acetylcholine–dopamine balance to relieve dystonia and tremor. This mechanism is fundamentally different from the core pathophysiology proposed for ADHD, which centres on prefrontal dopaminergic and noradrenergic underactivity.
The single literature reference supporting this prediction (PMID 21506147) is a case series describing tic disorder associated with dystonia — it does not evaluate trihexyphenidyl’s efficacy in ADHD, nor does it discuss ADHD at all. The topical overlap (movement disorder terminology) is therefore likely to reflect proximity in the knowledge graph embedding rather than a genuine treatment signal.
Given the absence of both a confirmed mechanistic rationale and direct clinical evidence, this prediction should currently be regarded as hypothesis-generating only, not as a basis for clinical or regulatory action.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21506147 | 2011 | Case Series | Movement Disorders | Describes a clinical syndrome of primary tic disorder associated with dystonia; does not evaluate trihexyphenidyl or ADHD directly |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (ADHD) is not supported by any direct clinical trial or literature evidence, and the single cited publication is only topically adjacent (tic/dystonia case series), not a treatment study. Mechanism of action data is also unavailable, preventing assessment of biological plausibility. The drug currently has no UK marketing authorisation.
To proceed, the following is needed:
- Mechanism of action (MOA) data for trihexyphenidyl
- Confirmed original indication and regulatory history
- Product label warnings and contraindications (currently a Blocking-severity data gap; needed before any safety pre-screening can proceed)
- Direct clinical or preclinical evidence specifically evaluating trihexyphenidyl in ADHD
- As a lower-priority research lead: rank 5 (PLA2G6-associated neurodegeneration, score 99.58%, evidence level L4, decision stage S1 — “Research Question”) shows a more coherent mechanistic rationale, as dystonia-parkinsonism is a recognised phenotype in this disease group and anticholinergics are used symptomatically in related NBIA disorders. This candidate may warrant closer follow-up despite the lack of drug-specific efficacy data.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.